ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options

While more pharmas big and small are pursuing “off-the-shelf” CAR-T therapies, Novartis has been blazing its own trail. The Swiss drugmaker has been fine-tuning its T-Charge platform to speed up the process by ensuring most of the CAR T-cell expansion occurs within a patient’s body.